ClinicalTrials.gg

Program

fxs7553 dose

A development code. Also written as “EXPD-101/FXS7553 Dose 1” and “EXPD-101/FXS7553 Dose 2”.

Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by Expedition Therapeutics.

Furthest: phase 2, since May 6, 20261 company-led study, 1 open or runningNext primary completion: Jun 30, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Expedition Therapeutics11 open or runningphase 2since May 6, 2026May 6, 2026Jun 30, 2028phase 2 · NCT07684820
  • Named in fosun pharma’s own pipeline as FXS7553 (DPP1), phase 2, as of Sep 21, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 6, 2026First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT07684820 · 600 planned · United States, Canada, Georgia and more

Ahead

  1. Jun 30, 2028Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07684820

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07684820Pulmonary Disease, Chronic Obstructive · United States, Canada, Georgia and more2RecruitingJun 30, 2028600

How it is read

Names in the registry

  • “EXPD-101/FXS7553 Dose 1”, 1 entry
  • “EXPD-101/FXS7553 Dose 2”, 1 entry

Codes read as this program: FXS7553.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.